ERBB2 and endocervical adenocarcinoma: 1. Expert gynecologic pathologists should take the lead in developing robust guidelines for testing and scoring HER2 and PDL1 immunohistochemistry to facilitate standardization in clinical trials. It is strongly recommended to interpret and report predictive biomarkers to response of treatment in endocervical adenocarcinoma in correlation with well-established pathologic parameters